# Patent

## Title
Organic light emitting materials

## Abstract

Phosphorescent iridium complexes comprising multi-alkyl-substituted aza-DBF and 2-phenylpyridine ligands is disclosed. These complexes are useful as emitters for phosphorescent OLEDs.

## Background
PARTIES TO A JOINT RESEARCH AGREEMENT
The claimed invention was made by, on behalf of, and/or in connection with one or more of the following parties to a joint university corporation research agreement: The Regents of the University of Michigan, Princeton University, University of Southern California, and Universal Display Corporation. The agreement was in effect on and before the date the claimed invention was made, and the claimed invention was made as a result of activities undertaken within the scope of the agreement.
FIELD OF THE INVENTION
The present invention relates to compounds for use as phosphorescent emitters and devices, such as organic light emitting diodes, including the same.
BACKGROUND
Opto-electronic devices that make use of organic materials are becoming increasingly desirable for a number of reasons. Many of the materials used to make such devices are relatively inexpensive, so organic opto-electronic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials, such as their flexibility, may make them well suited for particular applications such as fabrication on a flexible substrate. Examples of organic opto-electronic devices include organic light emitting devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, the organic materials may have performance advantages over conventional materials. For example, the wavelength at which an organic emissive layer emits light may generally be readily tuned with appropriate dopants.
OLEDs make use of thin organic films that emit light when voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for use in applications such as flat panel displays, illumination, and backlighting. Several OLED materials and configurations are described in U.S. Pat. Nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.
One application for phosphorescent emissive molecules is a full color display. Industry standards for such a display call for pixels adapted to emit particular colors, referred to as “saturated” colors. In particular, these standards call for saturated red, green, and blue pixels. Color may be measured using CIE coordinates, which are well known to the art.
One example of a green emissive molecule is tris(2-phenylpyridine) iridium, denoted Ir(ppy)3, which has the following structure:




In this, and later figures herein, we depict the dative bond from nitrogen to metal (here, Ir) as a straight line.
As used herein, the term “organic” includes polymeric materials as well as small molecule organic materials that may be used to fabricate organic opto-electronic devices. “Small molecule” refers to any organic material that is not a polymer, and “small molecules” may actually be quite large. Small molecules may include repeat units in some circumstances. For example, using a long chain alkyl group as a substituent does not remove a molecule from the “small molecule” class. Small molecules may also be incorporated into polymers, for example as a pendent group on a polymer backbone or as a part of the backbone. Small molecules may also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of a dendrimer may be a fluorescent or phosphorescent small molecule emitter. A dendrimer may be a “small molecule,” and it is believed that all dendrimers currently used in the field of OLEDs are small molecules.
As used herein, “top” means furthest away from the substrate, while “bottom” means closest to the substrate. Where a first layer is described as “disposed over” a second layer, the first layer is disposed further away from substrate. There may be other layers between the first and second layer, unless it is specified that the first layer is “in contact with” the second layer. For example, a cathode may be described as “disposed over” an anode, even though there are various organic layers in between.
As used herein, “solution processible” means capable of being dissolved, dispersed, or transported in and/or deposited from a liquid medium, either in solution or suspension form.
A ligand may be referred to as “photoactive” when it is believed that the ligand directly contributes to the photoactive properties of an emissive material. A ligand may be referred to as “ancillary” when it is believed that the ligand does not contribute to the photoactive properties of an emissive material, although an ancillary ligand may alter the properties of a photoactive ligand.
As used herein, and as would be generally understood by one skilled in the art, a first “Highest Occupied Molecular Orbital” (HOMO) or “Lowest Unoccupied Molecular Orbital” (LUMO) energy level is “greater than” or “higher than” a second HOMO or LUMO energy level if the first energy level is closer to the vacuum energy level. Since ionization potentials (IP) are measured as a negative energy relative to a vacuum level, a higher HOMO energy level corresponds to an IP having a smaller absolute value (an IP that is less negative). Similarly, a higher LUMO energy level corresponds to an electron affinity (EA) having a smaller absolute value (an EA that is less negative). On a conventional energy level diagram, with the vacuum level at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. A “higher” HOMO or LUMO energy level appears closer to the top of such a diagram than a “lower” HOMO or LUMO energy level.
As used herein, and as would be generally understood by one skilled in the art, a first work function is “greater than” or “higher than” a second work function if the first work function has a higher absolute value. Because work functions are generally measured as negative numbers relative to vacuum level, this means that a “higher” work function is more negative. On a conventional energy level diagram, with the vacuum level at the top, a “higher” work function is illustrated as further away from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different convention than work functions.
More details on OLEDs, and the definitions described above, can be found in U.S. Pat. No. 7,279,704, which is incorporated herein by reference in its entirety.
SUMMARY OF THE INVENTION
According to an embodiment, a compound having the formula Ir(LA)n(LB)3-n, having the structure according to Formula I shown below is disclosed:




In Formula I, Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;

wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, deuterium, aryl, alkyl, cycloalkyl, and combinations thereof;
wherein at least two of R1, R2, R3, and R4 are alkyl, cycloalkyl, or combinations thereof; and
wherein any adjacent substitutions in R1 to R4 and Ra to Rc are optionally linked together to form a ring.
According to another embodiment, a device comprising one or more organic light emitting devices is also provided. At least one of the one or more organic light emitting devices can include an anode, a cathode, and an organic layer, wherein the organic layer comprises the compound having a formula Ir(LA)n(LB)3-n, having the structure according to Formula I disclosed herein. The device can be a consumer product, an electronic component module, an organic light-emitting device, and/or a lighting panel.
According to yet another embodiment, a formulation comprising the compound having a formula Ir(LA)n(LB)3-n, having the structure according to Formula I disclosed herein disclosed.
The present disclosure provides iridium complexes comprising multi-alkyl-substituted aza-DBF and 2-phenylpyridine ligands that are useful as emitters for phosphorescent OLEDs (PHOLEDs) by providing improved device performance such as CIE color and lifetime, etc.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows an organic light emitting device.
FIG. 2 shows an inverted organic light emitting device that does not have a separate electron transport layer.
FIG. 3 shows Formula I of the disclosed inventive compound.



DETAILED DESCRIPTION
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When a current is applied, the anode injects holes and the cathode injects electrons into the organic layer(s). The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and hole localize on the same molecule, an “exciton,” which is a localized electron-hole pair having an excited energy state, is formed. Light is emitted when the exciton relaxes via a photoemissive mechanism. In some cases, the exciton may be localized on an excimer or an exciplex. Non-radiative mechanisms, such as thermal relaxation, may also occur, but are generally considered undesirable.
The initial OLEDs used emissive molecules that emitted light from their singlet states (“fluorescence”) as disclosed, for example, in U.S. Pat. No. 4,769,292, which is incorporated by reference in its entirety. Fluorescent emission generally occurs in a time frame of less than 10 nanoseconds.
More recently, OLEDs having emissive materials that emit light from triplet states (“phosphorescence”) have been demonstrated. Baldo et al., “Highly Efficient Phosphorescent Emission from Organic Electroluminescent Devices,” Nature, vol. 395, 151-154, 1998; (“Baldo-I”) and Baldo et al., “Very high-efficiency green organic light-emitting devices based on electrophosphorescence,” Appl. Phys. Lett., vol. 75, No. 3, 4-6 (1999) (“Baldo-II”), which are incorporated by reference in their entireties. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704 at cols. 5-6, which are incorporated by reference.
FIG. 1 shows an organic light emitting device 100. The figures are not necessarily drawn to scale. Device 100 may include a substrate 110, an anode 115, a hole injection layer 120, a hole transport layer 125, an electron blocking layer 130, an emissive layer 135, a hole blocking layer 140, an electron transport layer 145, an electron injection layer 150, a protective layer 155, a cathode 160, and a barrier layer 170. Cathode 160 is a compound cathode having a first conductive layer 162 and a second conductive layer 164. Device 100 may be fabricated by depositing the layers described, in order. The properties and functions of these various layers, as well as example materials, are described in more detail in U.S. Pat. No. 7,279,704 at cols. 6-10, which are incorporated by reference.
More examples for each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is m-MTDATA doped with F4-TCNQ at a molar ratio of 50:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of emissive and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al., which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entireties, disclose examples of cathodes including compound cathodes having a thin layer of metal such as Mg:Ag with an overlying transparent, electrically-conductive, sputter-deposited ITO layer. The theory and use of blocking layers is described in more detail in U.S. Pat. No. 6,097,147 and U.S. Patent Application Publication No. 2003/0230980, which are incorporated by reference in their entireties. Examples of injection layers are provided in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of protective layers may be found in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety.
FIG. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. Device 200 may be fabricated by depositing the layers described, in order. Because the most common OLED configuration has a cathode disposed over the anode, and device 200 has cathode 215 disposed under anode 230, device 200 may be referred to as an “inverted” OLED. Materials similar to those described with respect to device 100 may be used in the corresponding layers of device 200. FIG. 2 provides one example of how some layers may be omitted from the structure of device 100.
The simple layered structure illustrated in FIGS. 1 and 2 is provided by way of non-limiting example, and it is understood that embodiments of the invention may be used in connection with a wide variety of other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be achieved by combining the various layers described in different ways, or layers may be omitted entirely, based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe various layers as comprising a single material, it is understood that combinations of materials, such as a mixture of host and dopant, or more generally a mixture, may be used. Also, the layers may have various sublayers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an “organic layer” disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to FIGS. 1 and 2.
Structures and materials not specifically described may also be used, such as OLEDs comprised of polymeric materials (PLEDs) such as disclosed in U.S. Pat. No. 5,247,190 to Friend et al., which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. OLEDs may be stacked, for example as described in U.S. Pat. No. 5,707,745 to Forrest et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in FIGS. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling, such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Forrest et al., and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Bulovic et al., which are incorporated by reference in their entireties.
Unless otherwise specified, any of the layers of the various embodiments may be deposited by any suitable method. For the organic layers, preferred methods include thermal evaporation, ink-jet, such as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, which are incorporated by reference in their entireties, organic vapor phase deposition (OVPD), such as described in U.S. Pat. No. 6,337,102 to Forrest et al., which is incorporated by reference in its entirety, and deposition by organic vapor jet printing (OVJP), such as described in U.S. Pat. No. 7,431,968, which is incorporated by reference in its entirety. Other suitable deposition methods include spin coating and other solution based processes. Solution based processes are preferably carried out in nitrogen or an inert atmosphere. For the other layers, preferred methods include thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding such as described in U.S. Pat. Nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entireties, and patterning associated with some of the deposition methods such as ink-jet and OVJD. Other methods may also be used. The materials to be deposited may be modified to make them compatible with a particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3-20 carbons is a preferred range. Materials with asymmetric structures may have better solution processibility than those having symmetric structures, because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated in accordance with embodiments of the present invention may further optionally comprise a barrier layer. One purpose of the barrier layer is to protect the electrodes and organic layers from damaging exposure to harmful species in the environment including moisture, vapor and/or gases, etc. The barrier layer may be deposited over, under or next to a substrate, an electrode, or over any other parts of a device including an edge. The barrier layer may comprise a single layer, or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase as well as compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic or an organic compound or both. The preferred barrier layer comprises a mixture of a polymeric material and a non-polymeric material as described in U.S. Pat. No. 7,968,146, PCT Pat. Application Nos. PCT/US2007/023098 and PCT/US2009/042829, which are herein incorporated by reference in their entireties. To be considered a “mixture”, the aforesaid polymeric and non-polymeric materials comprising the barrier layer should be deposited under the same reaction conditions and/or at the same time. The weight ratio of polymeric to non-polymeric material may be in the range of 95:5 to 5:95. The polymeric material and the non-polymeric material may be created from the same precursor material. In one example, the mixture of a polymeric material and a non-polymeric material consists essentially of polymeric silicon and inorganic silicon.
Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of electronic component modules (or units) that can be incorporated into a variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices such as discrete light source devices or lighting panels, etc. that can be utilized by the end-user product manufacturers. Such electronic component modules can optionally include the driving electronics and/or power source(s). Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of consumer products that have one or more of the electronic component modules (or units) incorporated therein. Such consumer products would include any kind of products that include one or more light source(s) and/or one or more of some type of visual displays. Some examples of such consumer products include flat panel displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, laser printers, telephones, cell phones, tablets, phablets, personal digital assistants (PDAs), laptop computers, digital cameras, camcorders, viewfinders, micro-displays, 3-D displays, vehicles, a large area wall, theater or stadium screen, or a sign. Various control mechanisms may be used to control devices fabricated in accordance with the present invention, including passive matrix and active matrix. Many of the devices are intended for use in a temperature range comfortable to humans, such as 18 degrees C. to 30 degrees C., and more preferably at room temperature (20-25 degrees C.), but could be used outside this temperature range, for example, from −40 degree C. to +80 degree C.
The materials and structures described herein may have applications in devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices, such as organic transistors, may employ the materials and structures.
The term “halo,” “halogen,” or “halide” as used herein includes fluorine, chlorine, bromine, and iodine.
The term “alkyl” as used herein contemplates both straight and branched chain alkyl radicals. Preferred alkyl groups are those containing from one to fifteen carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like. Additionally, the alkyl group may be optionally substituted.
The term “cycloalkyl” as used herein contemplates cyclic alkyl radicals. Preferred cycloalkyl groups are those containing 3 to 7 carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, and the like. Additionally, the cycloalkyl group may be optionally substituted.
The term “alkenyl” as used herein contemplates both straight and branched chain alkene radicals. Preferred alkenyl groups are those containing two to fifteen carbon atoms. Additionally, the alkenyl group may be optionally substituted.
The term “alkynyl” as used herein contemplates both straight and branched chain alkyne radicals. Preferred alkynyl groups are those containing two to fifteen carbon atoms. Additionally, the alkynyl group may be optionally substituted.
The terms “aralkyl” or “arylalkyl” as used herein are used interchangeably and contemplate an alkyl group that has as a substituent an aromatic group. Additionally, the aralkyl group may be optionally substituted.
The term “heterocyclic group” as used herein contemplates aromatic and non-aromatic cyclic radicals. Hetero-aromatic cyclic radicals also means heteroaryl. Preferred hetero-non-aromatic cyclic groups are those containing 3 or 7 ring atoms which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperdino, pyrrolidino, and the like, and cyclic ethers, such as tetrahydropyran, tetrahydropyran, and the like. Additionally, the heterocyclic group may be optionally substituted.
The term “aryl” or “aromatic group” as used herein contemplates single-ring groups and polycyclic ring systems. The polycyclic rings may have two or more rings in which two carbons are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the aryl group may be optionally substituted.
The term “heteroaryl” as used herein contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine and pyrimidine, and the like. The term heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the heteroaryl group may be optionally substituted.
The alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heterocyclic group, aryl, and heteroaryl may be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, cyclic amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfanyl, sulfonyl, phosphino, and combinations thereof.
As used herein, “substituted” indicates that a substituent other than H is bonded to the relevant position, such as carbon. Thus, for example, where R1 is mono-substituted, then one R1 must be other than H. Similarly, where R1 is di-substituted, then two of R1 must be other than H. Similarly, where R1 is unsubstituted, R1 is hydrogen for all available positions.
The “aza” designation in the fragments described herein, i.e. aza-dibenzofuran, aza-dibenzothiophene, etc. means that one or more of the C—H groups in the respective fragment can be replaced by a nitrogen atom, for example, and without any limitation, azatriphenylene encompasses both dibenzo[f,h]quinoxaline and dibenzo[f,h]quinoline. One of ordinary skill in the art can readily envision other nitrogen analogs of the aza-derivatives described above, and all such analogs are intended to be encompassed by the terms as set forth herein.
It is to be understood that when a molecular fragment is described as being a substituent or otherwise attached to another moiety, its name may be written as if it were a fragment (e.g. phenyl, phenylene, naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g. benzene, naphthalene, dibenzofuran). As used herein, these different ways of designating a substituent or attached fragment are considered to be equivalent.
The present disclosure provides a novel phosphorescent compound having the formula Ir(LA)n(LB)3-n, and having a structure of Formula I shown below:




In Formula I, Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;

wherein X is O, S, or Se; wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, deuterium, aryl, alkyl, cycloalkyl, and combinations thereof;
wherein at least two of R1, R2, R3, and R4 are alkyl, cycloalkyl, or combinations thereof; and
wherein any adjacent substitutions in R1 to R4 and Ra to Rc are optionally linked together to form a ring.
In some embodiments of the compound, at least two of R1, R2, R3, and R4 are each independently selected from the group consisting of methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, and combinations thereof, wherein each group is optionally partially or fully deuterated.
In one embodiment of the compound having the structure of Formula I, n is 1.
In one embodiment of the compound having the structure of Formula I, X is O.
In one embodiment of the compound having the structure of Formula I, R1 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R3 are hydrogen.
In another embodiment of the compound having the structure of Formula I, R1 and R3 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R4 are hydrogen.
In one embodiment of the compound having the structure of Formula I, R3 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R1 and R2 are hydrogen.
In one preferred embodiment of the compound having the structure of Formula I, R1, R3, and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated and R2 is hydrogen.
In one embodiment of the compound having the structure of Formula I, any two of R1, R2, R3, and R4 are hydrogen.
In another embodiment of the compound having the structure of Formula I, R1 is selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated.
In one embodiment of the compound, the total number of carbon atoms in R1, R2, R3, and R4 combined is at least 3. In another embodiment of the compound, the total number of carbon atoms in R1, R2, R3, and R4 is at least 4.
In one embodiment of the compound, Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In one embodiment of the compound, LA has a structure according to the following formula:




and is selected from the group consisting of LA1 through LA438 wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in Tables 1A and 1B provided below:
















TABLE 1A





Ligand










LA
R1
R2
R3
R4
R5
R6
R7
R8







LA1
CH3
CH3
H
H
H
H
H
H


LA2
CH3
H
CH3
H
H
H
H
H


LA3
CH3
H
H
CH3
H
H
H
H


LA4
H
CH3
CH3
H
H
H
H
H


LA5
H
CH3
H
CH3
H
H
H
H


LA6
H
H
CH3
CH3
H
H
H
H


LA7
CD3
CD3
H
H
H
H
H
H


LA8
CD3
H
CD3
H
H
H
H
H


LA9
CD3
H
H
CD3
H
H
H
H


LA10
H
CD3
CD3
H
H
H
H
H


LA11
H
CD3
H
CD3
H
H
H
H


LA12
H
H
CD3
CD3
H
H
H
H


LA13
CH3
CH3
H
H
CH3
H
H
H


LA14
CH3
H
CH3
H
CH3
H
H
H


LA15
CH3
H
H
CH3
CH3
H
H
H


LA16
H
CH3
CH3
H
CH3
H
H
H


LA17
H
CH3
H
CH3
CH3
H
H
H


LA18
H
H
CH3
CH3
CH3
H
H
H


LA19
CD3
CD3
H
H
CD3
H
H
H


LA20
CD3
H
CD3
H
CD3
H
H
H


LA21
CD3
H
H
CD3
CD3
H
H
H


LA22
H
CD3
CD3
H
CD3
H
H
H


LA23
H
CD3
H
CD3
CD3
H
H
H


LA24
H
H
CD3
CD3
CD3
H
H
H


LA25
CH3
CH3
H
H
H
CH3
H
H


LA26
CH3
H
CH3
H
H
CH3
H
H


LA27
CH3
H
H
CH3
H
CH3
H
H


LA28
H
CH3
CH3
H
H
CH3
H
H


LA29
H
CH3
H
CH3
H
CH3
H
H


LA30
H
H
CH3
CH3
H
CH3
H
H


LA31
CD3
CD3
H
H
H
CD3
H
H


LA32
CD3
H
CD3
H
H
CD3
H
H


LA33
CD3
H
H
CD3
H
CD3
H
H


LA34
H
CD3
CD3
H
H
CD3
H
H


LA35
H
CD3
H
CD3
H
CD3
H
H


LA36
H
H
CD3
CD3
H
CD3
H
H


LA37
CH3
CH3
H
H
H
H
CH3
H


LA38
CH3
H
CH3
H
H
H
CH3
H


LA39
CH3
H
H
CH3
H
H
CH3
H


LA40
H
CH3
CH3
H
H
H
CH3
H


LA41
H
CH3
H
CH3
H
H
CH3
H


LA42
H
H
CH3
CH3
H
H
CH3
H


LA43
CD3
CD3
H
H
H
H
CD3
H


LA44
CD3
H
CD3
H
H
H
CD3
H


LA45
CD3
H
H
CD3
H
H
CD3
H


LA46
H
CD3
CD3
H
H
H
CD3
H


LA47
H
CD3
H
CD3
H
H
CD3
H


LA48
H
H
CD3
CD3
H
H
CD3
H


LA49
CH3
CH3
H
H
H
H
H
CH3


LA50
CH3
H
CH3
H
H
H
H
CH3


LA51
CH3
H
H
CH3
H
H
H
CH3


LA52
H
CH3
CH3
H
H
H
H
CH3


LA53
H
CH3
H
CH3
H
H
H
CH3


LA54
H
H
CH3
CH3
H
H
H
CH3


LA55
CD3
CD3
H
H
H
H
H
CD3


LA56
CD3
H
CD3
H
H
H
H
CD3


LA57
CD3
H
H
CD3
H
H
H
CD3


LA58
H
CD3
CD3
H
H
H
H
CD3


LA59
H
CD3
H
CD3
H
H
H
CD3


LA60
H
H
CD3
CD3
H
H
H
CD3


LA61
CH3
CH3
H
H
CH(CH3)2
H
H
H


LA62
CH3
H
CH3
H
CH(CH3)2
H
H
H


LA63
CH3
H
H
CH3
CH(CH3)2
H
H
H


LA64
H
CH3
CH3
H
CH(CH3)2
H
H
H


LA65
H
CH3
H
CH3
CH(CH3)2
H
H
H


LA66
H
H
CH3
CH3
CH(CH3)2
H
H
H


LA67
CD3
CD3
H
H
CD(CD3)2
H
H
H


LA68
CD3
H
CD3
H
CD(CD3)2
H
H
H


LA69
CD3
H
H
CD3
CD(CD3)2
H
H
H


LA70
H
CD3
CD3
H
CD(CD3)2
H
H
H


LA71
H
CD3
H
CD3
CD(CD3)2
H
H
H


LA72
H
H
CD3
CD3
CD(CD3)2
H
H
H


LA73
CH3
CH3
H
H
H
CH(CH3)2
H
H


LA74
CH3
H
CH3
H
H
CH(CH3)2
H
H


LA75
CH3
H
H
CH3
H
CH(CH3)2
H
H


LA76
H
CH3
CH3
H
H
CH(CH3)2
H
H


LA77
H
CH3
H
CH3
H
CH(CH3)2
H
H


LA78
H
H
CH3
CH3
H
CH(CH3)2
H
H


LA79
CD3
CD3
H
H
H
CD(CD3)2
H
H


LA80
CD3
H
CD3
H
H
CD(CD3)2
H
H


LA81
CD3
H
H
CD3
H
CD(CD3)2
H
H


LA82
H
CD3
CD3
H
H
CD(CD3)2
H
H


LA83
H
CD3
H
CD3
H
CD(CD3)2
H
H


LA84
H
H
CD3
CD3
H
CD(CD3)2
H
H


LA85
CH3
CH3
H
H
H
H
CH(CH3)2
H


LA86
CH3
H
CH3
H
H
H
CH(CH3)2
H


LA87
CH3
H
H
CH3
H
H
CH(CH3)2
H


LA88
H
CH3
CH3
H
H
H
CH(CH3)2
H


LA89
H
CH3
H
CH3
H
H
CH(CH3)2
H


LA90
H
H
CH3
CH3
H
H
CH(CH3)2
H


LA91
CD3
CD3
H
H
H
H
CD(CD3)2
H


LA92
CD3
H
CD3
H
H
H
CD(CD3)2
H


LA93
CD3
H
H
CD3
H
H
CD(CD3)2
H


LA94
H
CD3
CD3
H
H
H
CD(CD3)2
H


LA95
H
CD3
H
CD3
H
H
CD(CD3)2
H


LA96
H
H
CD3
CD3
H
H
CD(CD3)2
H


LA97
CD3
H
CD3
H
H
H
CD(CH3)2
H


LA98
CH2CH3
CH3
H
H
H
CH(CH3)2
H
H


LA99
CH2CH3
H
CH3
H
H
CH(CH3)2
H
H


LA100
CH2CH3
H
H
CH3
H
CH(CH3)2
H
H


LA101
H
CH2CH3
CH3
H
H
CH(CH3)2
H
H


LA102
H
CH2CH3
H
CH3
H
CH(CH3)2
H
H


LA103
H
H
CH2CH3
CH3
H
CH(CH3)2
H
H


LA104
H
H
CH3
CH2CH3
H
CH(CH3)2
H
H


LA105
H
CH3
H
CH2CH3
H
CH(CH3)2
H
H


LA106
CH3
H
H
CH2CH3
H
CH(CH3)2
H
H


LA107
CD2CD3
CD3
H
H
H
CD(CD3)2
H
H


LA108
CD2CD3
H
CD3
H
H
CD(CD3)2
H
H


LA109
CD2CD3
H
H
CD3
H
CD(CD3)2
H
H


LA110
CD2CD3
H
H
CD3
H
CD(CH3)2
H
H


LA111
CH2CH3
CH3
H
H
H
H
CH(CH3)2
H


LA112
CH2CH3
H
CH3
H
H
H
CH(CH3)2
H


LA113
CH2CH3
H
H
CH3
H
H
CH(CH3)2
H


LA114
H
CH2CH3
CH3
H
H
H
CH(CH3)2
H


LA115
H
CH2CH3
H
CH3
H
H
CH(CH3)2
H


LA116
H
H
CH2CH3
CH3
H
H
CH(CH3)2
H


LA117
H
H
CH3
CH2CH3
H
H
CH(CH3)2
H


LA118
H
CH3
H
CH2CH3
H
H
CH(CH3)2
H


LA119
CH3
H
H
CH2CH3
H
H
CH(CH3)2
H


LA120
CD2CD3
CD3
H
H
H
H
CD(CD3)2
H


LA121
CD2CD3
H
CD3
H
H
H
CD(CD3)2
H


LA122
CD2CD3
H
H
CD3
H
H
CD(CD3)2
H


LA123
CD3
H
H
CD2CH3
H
H
CD(CH3)2
H


LA124
CD3
H
H
CD2CH3
H
H
H
CD3


LA125
CH3
CH3
H
H
H
H
H
CH(CH3)2


LA126
CH3
H
CH3
H
H
H
H
CH(CH3)2


LA127
CH3
H
H
CH3
H
H
H
CH(CH3)2


LA128
H
CH3
CH3
H
H
H
H
CH(CH3)2


LA129
H
CH3
H
CH3
H
H
H
CH(CH3)2


LA130
H
H
CH3
CH3
H
H
H
CH(CH3)2


LA131
CD3
CD3
H
H
H
H
H
CD(CD3)2


LA132
CD3
H
CD3
H
H
H
H
CD(CD3)2


LA133
CD3
H
H
CD3
H
H
H
CD(CD3)2


LA134
H
CD3
CD3
H
H
H
H
CD(CD3)2


LA135
H
CD3
H
CD3
H
H
H
CD(CD3)2


LA136
H
H
CD3
CD3
H
H
H
CD(CD3)2


LA137
CH3
CH3
H
H
H
CH2CH(CH3)2
H
H


LA138
CH3
H
CH3
H
H
CH2CH(CH3)2
H
H


LA139
CH3
H
H
CH3
H
CH2CH(CH3)2
H
H


LA140
H
CH3
CH3
H
H
CH2CH(CH3)2
H
H


LA141
H
CH3
H
CH3
H
CH2CH(CH3)2
H
H


LA142
H
H
CH3
CH3
H
CH2CH(CH3)2
H
H


LA143
CD3
CD3
H
H
H
CD2CH(CH3)2
H
H


LA144
CD3
H
CD3
H
H
CD2CH(CH3)2
H
H


LA145
CD3
H
H
CD3
H
CD2CH(CH3)2
H
H


LA146
H
CD3
CD3
H
H
CD2CH(CH3)2
H
H


LA147
H
CD3
H
CD3
H
CD2CH(CH3)2
H
H


LA148
H
H
CD3
CD3
H
CD2CH(CH3)2
H
H


LA149
CH3
CH3
H
H
H
H
CH2CH(CH3)2
H


LA150
CH3
H
CH3
H
H
H
CH2CH(CH3)2
H


LA151
CH3
H
H
CH3
H
H
CH2CH(CH3)2
H


LA152
H
CH3
CH3
H
H
H
CH2CH(CH3)2
H


LA153
H
CH3
H
CH3
H
H
CH2CH(CH3)2
H


LA154
H
H
CH3
CH3
H
H
CH2CH(CH3)2
H


LA155
CD3
CD3
H
H
H
H
CD2CH(CH3)2
H


LA156
CD3
H
CD3
H
H
H
CD2CH(CH3)2
H


LA157
CD3
H
H
CD3
H
H
CD2CH(CH3)2
H


LA158
H
CD3
CD3
H
H
H
CD2CH(CH3)2
H


LA159
H
CD3
H
CD3
H
H
CD2CH(CH3)2
H


LA160
H
H
CD3
CD3
H
H
CD2CH(CH3)2
H


LA161
CH3
CH3
H
H
CH3
CH3
H
H


LA162
CH3
H
CH3
H
CH3
CH3
H
H


LA163
CH3
H
H
CH3
CH3
CH3
H
H


LA164
H
CH3
CH3
H
CH3
CH3
H
H


LA165
H
CH3
H
CH3
CH3
CH3
H
H


LA166
H
H
CH3
CH3
CH3
CH3
H
H


LA167
CD3
CD3
H
H
CD3
CD3
H
H


LA168
CD3
H
CD3
H
CD3
CD3
H
H


LA169
CD3
H
H
CD3
CD3
CD3
H
H


LA170
H
CD3
CD3
H
CD3
CD3
H
H


LA171
H
CD3
H
CD3
CD3
CD3
H
H


LA172
H
H
CD3
CD3
CD3
CD3
H
H


LA173
CH3
CH3
H
H
H
CH3
CH3
H


LA174
CH3
H
CH3
H
H
CH3
CH3
H


LA175
CH3
H
H
CH3
H
CH3
CH3
H


LA176
H
CH3
CH3
H
H
CH3
CH3
H


LA177
H
CH3
H
CH3
H
CH3
CH3
H


LA178
H
H
CH3
CH3
H
CH3
CH3
H


LA179
CD3
CD3
H
H
H
CD3
CD3
H


LA180
CD3
H
CD3
H
H
CD3
CD3
H


LA181
CD3
H
H
CD3
H
CD3
CD3
H


LA182
H
CD3
CD3
H
H
CD3
CD3
H


LA183
H
CD3
H
CD3
H
CD3
CD3
H


LA184
H
H
CD3
CD3
H
CD3
CD3
H


LA185
CH3
CH3
H
H
H
CH(CH3)2
CH3
H


LA186
CH3
H
CH3
H
H
CH(CH3)2
CH3
H


LA187
CH3
H
H
CH3
H
CH(CH3)2
CH3
H


LA188
H
CH3
CH3
H
H
CH(CH3)2
CH3
H


LA189
H
CH3
H
CH3
H
CH(CH3)2
CH3
H


LA190
H
H
CH3
CH3
H
CH(CH3)2
CH3
H


LA191
CD3
CD3
H
H
H
CD(CD3)2
CD3
H


LA192
CD3
H
CD3
H
H
CD(CD3)2
CD3
H


LA193
CD3
H
H
CD3
H
CD(CD3)2
CD3
H


LA194
H
CD3
CD3
H
H
CD(CD3)2
CD3
H


LA195
H
CD3
H
CD3
H
CD(CD3)2
CD3
H


LA196
H
H
CD3
CD3
H
CD(CD3)2
CD3
H


LA197
CH3
CH3
H
H
H
CH3
CH(CH3)2
H


LA198
CH3
H
CH3
H
H
CH3
CH(CH3)2
H


LA199
CH3
H
H
CH3
H
CH3
CH(CH3)2
H


LA200
H
CH3
CH3
H
H
CH3
CH(CH3)2
H


LA201
H
CH3
H
CH3
H
CH3
CH(CH3)2
H


LA202
H
H
CH3
CH3
H
CH3
CH(CH3)2
H


LA203
CD3
CD3
H
H
H
CD3
CD(CD3)2
H


LA204
CD3
H
CD3
H
H
CD3
CD(CD3)2
H


LA205
CD3
H
H
CD3
H
CD3
CD(CD3)2
H


LA206
H
CD3
CD3
H
H
CD3
CD(CD3)2
H


LA207
H
CD3
H
CD3
H
CD3
CD(CD3)2
H


LA208
H
H
CD3
CD3
H
CD3
CD(CD3)2
H


LA209
CH3
CH3
H
H
H
CH2CH(CH3)2
CH3
H


LA210
CH3
H
CH3
H
H
CH2CH(CH3)2
CH3
H


LA211
CH3
H
H
CH3
H
CH2CH(CH3)2
CH3
H


LA212
H
CH3
CH3
H
H
CH2CH(CH3)2
CH3
H


LA213
H
CH3
H
CH3
H
CH2CH(CH3)2
CH3
H


LA214
H
H
CH3
CH3
H
CH2CH(CH3)2
CH3
H


LA215
CD3
CD3
H
H
H
CD2CH(CH3)2
CD3
H


LA216
CD3
H
CD3
H
H
CD2CH(CH3)2
CD3
H


LA217
CD3
H
H
CD3
H
CD2CH(CH3)2
CD3
H


LA218
H
CD3
CD3
H
H
CD2CH(CH3)2
CD3
H


LA219
H
CD3
H
CD3
H
CD2CH(CH3)2
CD3
H


LA220
H
H
CD3
CD3
H
CD2CH(CH3)2
CD3
H


LA221
CH3
CH3
H
H
H
CH3
CH2CH(CH3)2
H


LA222
CH3
H
CH3
H
H
CH3
CH2CH(CH3)2
H


LA223
CH3
H
H
CH3
H
CH3
CH2CH(CH3)2
H


LA224
H
CH3
CH3
H
H
CH3
CH2CH(CH3)2
H


LA225
H
CH3
H
CH3
H
CH3
CH2CH(CH3)2
H


LA226
H
H
CH3
CH3
H
CH3
CH2CH(CH3)2
H


LA227
CD3
CD3
H
H
H
CD3
CD2CH(CH3)2
H


LA228
CD3
H
CD3
H
H
CD3
CD2CH(CH3)2
H


LA229
CD3
H
H
CD3
H
CD3
CD2CH(CH3)2
H


LA230
H
CD3
CD3
H
H
CD3
CD2CH(CH3)2
H


LA231
H
CD3
H
CD3
H
CD3
CD2CH(CH3)2
H


LA232
H
H
CD3
CD3
H
CD3
CD2CH(CH3)2
H


LA233
CH(CH3)2
CH3
H
H
H
H
H
H


LA234
CH3
CH(CH3)2
H
H
H
H
H
H


LA235
CH(CH3)2
H
CH3
H
H
H
H
H


LA236
CH3
H
CH(CH3)2
H
H
H
H
H


LA237
CH(CH3)2
H
H
CH3
H
H
H
H


LA238
CH3
H
H
CH(CH3)2
H
H
H
H


LA239
H
CH(CH3)2
CH3
H
H
H
H
H


LA240
H
CH(CH3)2
H
CH3
H
H
H
H


LA241
H
H
CH(CH3)2
CH3
H
H
H
H


LA242
CH(CH3)2
H
H
CH(CH3)2
H
H
H
H


LA243
CD(CH3)2
CD3
H
H
H
H
H
H


LA244
CD(CH3)2
H
CD3
H
H
H
H
H


LA245
CD(CH3)2
H
H
CD3
H
H
H
H


LA246
H
CD(CH3)2
CD3
H
H
H
H
H


LA247
H
CD(CH3)2
H
CD3
H
H
H
H


LA248
CD3
H
H
CD(CH3)2
H
H
H
H


LA249
CD(CH3)2
H
CD(CH3)2
H
H
H
H
H


LA250
CD(CH3)2
H
H
CD(CH3)2
H
H
H
H


LA251
CH(CH3)2
CH3
H
H
H
CH(CH3)2
H
H


LA252
CH3
CH(CH3)2
H
H
H
CH(CH3)2
H
H


LA253
CH(CH3)2
H
CH3
H
H
CH(CH3)2
H
H


LA254
CH3
H
CH(CH3)2
H
H
CH(CH3)2
H
H


LA255
CH(CH3)2
H
H
CH3
H
CH(CH3)2
H
H


LA256
CH3
H
H
CH(CH3)2
H
CH(CH3)2
H
H


LA257
H
CH(CH3)2
CH3
H
H
CH(CH3)2
H
H


LA258
H
CH(CH3)2
H
CH3
H
CH(CH3)2
H
H


LA259
H
H
CH(CH3)2
CH3
H
CH(CH3)2
H
H


LA260
CH(CH3)2
H
H
CH(CH3)2
H
CH(CH3)2
H
H


LA261
CD(CH3)2
CD3
H
H
H
CD(CD3)2
H
H


LA262
CD(CH3)2
H
CD3
H
H
CD(CD3)2
H
H


LA263
CD(CH3)2
H
H
CD3
H
CD(CD3)2
H
H


LA264
H
CD(CH3)2
CD3
H
H
CD(CD3)2
H
H


LA265
H
CD(CH3)2
H
CD3
H
CD(CD3)2
H
H


LA266
CD3
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA267
CD(CH3)2
H
CD(CH3)2
H
H
CD(CD3)2
H
H


LA268
CD(CH3)2
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA269
CH(CH3)2
CH3
H
H
H
CH3
CH(CH3)2
H


LA270
CH3
CH(CH3)2
H
H
H
CH3
CH(CH3)2
H


LA271
CH(CH3)2
H
CH3
H
H
CH3
CH(CH3)2
H


LA272
CH3
H
CH(CH3)2
H
H
CH3
CH(CH3)2
H


LA273
CH(CH3)2
H
H
CH3
H
CH3
CH(CH3)2
H


LA274
CH3
H
H
CH(CH3)2
H
CH3
CH(CH3)2
H


LA275
H
CH(CH3)2
CH3
H
H
CH3
CH(CH3)2
H


LA276
H
CH(CH3)2
H
CH3
H
CH3
CH(CH3)2
H


LA277
H
H
CH(CH3)2
CH3
H
CH3
CH(CH3)2
H


LA278
CH(CH3)2
H
H
CH(CH3)2
H
CH3
CH(CH3)2
H


LA279
CD(CH3)2
CD3
H
H
H
CD3
CH(CH3)2
H


LA280
CD(CH3)2
H
CD3
H
H
CD3
CH(CH3)2
H


LA281
CD(CH3)2
H
H
CD3
H
CD3
CH(CH3)2
H


LA282
H
CD(CH3)2
CD3
H
H
CD3
CH(CH3)2
H


LA283
H
CD(CH3)2
H
CD3
H
CD3
CH(CH3)2
H


LA284
CD3
H
H
CD(CH3)2
H
CD3
CH(CH3)2
H


LA285
CD(CH3)2
H
CD(CH3)2
H
H
CD3
CH(CH3)2
H


LA286
CD(CH3)2
H
H
CD(CH3)2
H
CD3
CH(CH3)2
H


LA287
CH(CH3)2
CH3
H
H
H
CH(CH3)2
CH3
H


LA288
CH3
CH(CH3)2
H
H
H
CH(CH3)2
CH3
H


LA289
CH(CH3)2
H
CH3
H
H
CH(CH3)2
CH3
H


LA290
CH3
H
CH(CH3)2
H
H
CH(CH3)2
CH3
H


LA291
CH(CH3)2
H
H
CH3
H
CH(CH3)2
CH3
H


LA292
CH3
H
H
CH(CH3)2
H
CH(CH3)2
CH3
H


LA293
H
CH(CH3)2
CH3
H
H
CH(CH3)2
CH3
H


LA294
H
CH(CH3)2
H
CH3
H
CH(CH3)2
CH3
H


LA295
H
H
CH(CH3)2
CH3
H
CH(CH3)2
CH3
H


LA296
CH(CH3)2
H
H
CH(CH3)2
H
CD(CH3)2
CH3
H


LA297
CD(CH3)2
CD3
H
H
H
CD(CH3)2
CD3
H


LA298
CD(CH3)2
H
CD3
H
H
CD(CH3)2
CD3
H


LA299
CD(CH3)2
H
H
CD3
H
CD(CH3)2
CD3
H


LA300
H
CD(CH3)2
CD3
H
H
CD(CH3)2
CD3
H


LA301
H
CD(CH3)2
H
CD3
H
CD(CH3)2
CD3
H


LA302
CD3
H
H
CD(CH3)2
H
CD(CH3)2
CD3
H


LA303
CD(CH3)2
H
CD(CH3)2
H
H
CD(CH3)2
CD3
H


LA304
CD(CH3)2
H
H
CD(CH3)2
H
CD(CH3)2
CD3
H


LA305
CD(CH3)2
H
H
CD(CH3)2
H
CD(CD3)2
CD3
H


LA306
CD3
CD3
H
H
H
CD(CH3)2
H
H


LA307
CD3
H
CD3
H
H
CD(CH3)2
H
H


LA308
CD3
H
H
CD3
H
CD(CH3)2
H
H


LA309
H
CD3
CD3
H
H
CD(CH3)2
H
H


LA310
H
CD3
H
CD3
H
CD(CH3)2
H
H


LA311
H
H
CD3
CD3
H
CD(CH3)2
H
H


LA312
CH3
CH3
CH3
CH3
H
H
H
H


LA313
CH3
CH3
CH3
H
H
H
H
H


LA314
CH3
H
CH3
CH3
H
H
H
H


LA315
H
CH3
CH3
CH3
H
H
H
H


LA316
CD3
CD3
CD3
H
H
H
H
H


LA317
CD3
H
CD3
CD3
H
H
H
H


LA318
CD3
CD3
H
CD3
H
H
H
H


LA319
H
CD3
CD3
CD3
H
H
H
H


LA320
CD3
CD3
CD3
CD3
H
H
H
H


LA321
CD3
H
CD3
CD3
H
CD(CD3)2
H
H


LA322
CD3
H
CD3
CD3
H
H
CD(CD3)2
H


LA323
CD3
H
CD3
CD3
H
CD(CD3)2
CD3
H


LA324
CD3
H
CD3
CD3
H
CD3
CD(CD3)2
H


LA325
CD3
H
CD3
CD(CH3)2
H
H
H
H


LA326
CD3
H
CD3
CD(CH3)2
H
CD(CD3)2
H
H


LA327
CD3
H
CD3
CD(CH3)2
H
H
CD(CD3)2
H


LA328
CD3
H
CD3
CD(CH3)2
H
CD(CD3)2
CD3
H


LA329
CD3
H
CD3
CD(CH3)2
H
CD3
CD(CD3)2
H


LA330
CD3
H
CD(CH3)2
CD3
H
H
H
H


LA331
CD3
H
CD(CH3)2
CD3
H
CD(CD3)2
H
H


LA332
CD3
H
CD(CH3)2
CD3
H
H
CD(CD3)2
H


LA333
CD3
H
CD(CH3)2
CD3
H
CD(CD3)2
CD3
H


LA334
CD3
H
CD(CH3)2
CD3
H
CD3
CD(CD3)2
H


LA335
CD3
H
CD(CH3)2
CD(CH3)2
H
H
H
H


LA336
CD3
H
CD(CH3)2
CD(CH3)2
H
CD(CD3)2
H
H


LA337
CD3
H
CD(CH3)2
CD(CH3)2
H
H
CD(CD3)2
H


LA338
CD3
H
CD(CH3)2
CD(CH3)2
H
CD(CD3)2
CD3
H


LA339
CD3
H
CD(CH3)2
CD(CH3)2
H
CD3
CD(CD3)2
H


LA340
CD(CH3)2
H
CD3
H
H
H
CD(CD3)2
H


LA341
CD(CH3)2
H
CD3
H
H
CD3
CD(CD3)2
H


LA342
CD(CH3)2
H
CD3
H
H
CD(CD3)2
CD3
H


LA343
CD(CH3)2
H
CD3
CD3
H
H
H
H


LA344
CD(CH3)2
H
CD3
CD3
H
CD(CD3)2
H
H


LA345
CD(CH3)2
H
CD3
CD3
H
H
CD(CD3)2
H


LA346
CD(CH3)2
H
CD3
CD3
H
CD3
CD(CD3)2
H


LA347
CD(CH3)2
H
CD3
CD3
H
CD(CD3)2
CD3
H


LA348
CD3
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA349
CD3
H
H
CD(CH3)2
H
H
CD(CD3)2
H


LA350
CD3
H
H
CD(CH3)2
H
CD(CD3)2
CD3
H


LA351
CD3
H
H
CD(CH3)2
H
CD3
CD(CD3)2
H


LA352
CD3
H
CD(CH3)2
H
H
H
H
H


LA353
CD3
H
CD(CH3)2
H
H
CD(CD3)2
H
H


LA354
CD3
H
CD(CH3)2
H
H
H
CD(CD3)2
H


LA355
CD3
H
CD(CH3)2
H
H
CD(CD3)2
CD3
H


LA356
CD3
H
CD(CH3)2
H
H
CD3
CD(CD3)2
H
























TABLE 1B





Ligand LA
R1
R2
R3
R4
R5
R6
R7
R8







LA357




CH3
H
H
H
H
H
H


 


LA358




H
CH3
H
H
H
H
H


 


LA359




H
H
CH3
H
H
H
H


 


LA360
H




CH3
H
H
H
H
H


 


LA361
H




H
CH3
H
H
H
H


 


LA362
H
H




CH3
H
H
H
H


 


LA363
CH3
H
H




H
H
H
H


 


LA364
H
CH3
H




H
H
H
H


 


LA365
H
H
CH3




H
H
H
H


 


LA366




CD3
H
H
H
H
H
H


 


LA367




H
CD3
H
H
H
H
H


 


LA368




H
H
CD3
H
H
H
H


 


LA369
H




CD3
H
H
H
H
H


 


LA370
H




H
CD3
H
H
H
H


 


LA371
H
H




CD3
H
H
H
H


 


LA372
CD3
H
H




H
H
H
H


 


LA373
H
CD3
H




H
H
H
H


 


LA374
H
H
CD3




H
H
H
H


 


LA375




CH3
H
H
H
H
H
H


 


LA376




H
CH3
H
H
H
H
H


 


LA377




H
H
CH3
H
H
H
H


 


LA378
H




CH3
H
H
H
H
H


 


LA379
H




H
CH3
H
H
H
H


 


LA380
H
H




CH3
H
H
H
H


 


LA381
CH3
H
H




H
H
H
H


 


LA382
H
CH3
H




H
H
H
H


 


LA383
H
H
CH3




H
H
H
H


 


LA384




CD3
H
H
H
H
H
H


 


LA385




H
CD3
H
H
H
H
H


 


LA386




H
H
CD3
H
H
H
H


 


LA387
H




CD3
H
H
H
H
H


 


LA388
H




H
CD3
H
H
H
H


 


LA389
H
H




CD3
H
H
H
H


 


LA390
CD3
H
H




H
H
H
H


 


LA391
H
CD3
H




H
H
H
H


 


LA392
H
H
CD3




H
H
H
H


 


LA393




H
H
CH3
H
H
CH3
H


 


LA394




CH3
H
H
H
CH(CH3)2
H
H


 


LA395




H
CH3
H
H
CH(CH3)2
H
H


 


LA396




H
H
CH3
H
CH(CH3)2
H
H


 


LA397
H




CH3
H
H
CH(CH3)2
H
H


 


LA398
H




H
CH3
H
CH(CH3)2
H
H


 


LA399
H
H




CH3
H
CH(CH3)2
H
H


 


LA400




CD3
H
H
H
CD(CD3)2
H
H


 


LA401




H
CD3
H
H
CD(CD3)2
H
H


 


LA402




H
H
CD3
H
CD(CD3)2
H
H


 


LA403
H




CD3
H
H
CD(CD3)2
H
H


 


LA404
H




H
CD3
H
CD(CD3)2
H
H


 


LA405
H
H




CD3
H
CD(CD3)2
H
H


 


LA406




CD3
H
H
H
CD(CH3)2
H
H


 


LA407




H
CD3
H
H
CD(CH3)2
H
H


 


LA408




H
H
CD3
H
CD(CH3)2
H
H


 


LA409
H




CD3
H
H
CD(CH3)2
H
H


 


LA410
H




H
CD3
H
CD(CH3)2
H
H


 


LA411
H
H




CD3
H
CD(CH3)2
H
H


 


LA412




H
CH3
H
H
CD(CD3)2
H
H


 


LA413




CH3
H
H
H
CH(CH3)2
H
H


 


LA414




H
CH3
H
H
CH(CH3)2
H
H


 


LA415




H
H
CH3
H
CH(CH3)2
H
H


 


LA416
H




CH3
H
H
CH(CH3)2
H
H


 


LA417
H




H
CH3
H
CH(CH3)2
H
H


 


LA418
H
H




CH3
H
CH(CH3)2
H
H


 


LA4194




CD3
H
H
H
CD(CD3)2
H
H


 


LA420




H
CD3
H
H
CD(CD3)2
H
H


 


LA421




H
H
CD3
H
CD(CD3)2
H
H


 


LA422
H




CD3
H
H
CD(CD3)2
H
H


 


LA423
H




H
CD3
H
CD(CD3)2
H
H


 


LA424
H
H




CD3
H
CD(CD3)2
H
H


 


LA425




CD3
H
H
H
CD(CH3)2
H
H


 


LA426




H
CD3
H
H
CD(CH3)2
H
H


 


LA427 




H
H
CD3
H
CD(CH3)2
H
H


 


LA428
H




CD3
H
H
CD(CH3)2
H
H


 


LA429
H




H
CD3
H
CD(CH3)2
H
H


 


LA430
H
H




CD3
H
CD(CH3)2
H
H


 


LA431
CD3
H
H




H
CD(CH3)2
H
H


 


LA432
H
H
CD3




H
CD(CH3)2
H
H


 


LA433
H
CD3
H




H
CD(CH3)2
H
H


 


LA434




H
H




H
CD(CH3)2
H
H


 


LA435




H
H




H
CD(CH3)2
H
H


 


LA436




H
H




H
CD(CH3)2
H
H


 


LA437




H
H




H
CD(CH3)2
H
H


 


LA438




H
H




H
CD(CH3)2
H
H









In another embodiment of the compound, LB is selected from the group consisting of:















































































In one embodiment of the compound, the compound is selected from the group consisting of:
























































































According to another aspect of the present disclosure, a device comprising one or more organic light emitting devices is disclosed. At least one of the one or more organic light emitting devices comprise: an anode; a cathode; and an organic layer disposed between the anode and the cathode. The organic layer comprises a compound having the formula Ir(LA)n(LB)3-n, and having the structure according to Formula I shown below:




In Formula I, Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;

wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, deuterium, aryl, alkyl, cycloalkyl, and combinations thereof;
wherein at least two of R1, R2, R3, and R4 are alkyl, cycloalkyl, or combinations thereof; and
wherein any adjacent substitutions in R1 to R4 and Ra to Rc are optionally linked together to form a ring.
In one embodiment of the device, the device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel.
In some embodiments of the device, the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant.
The organic layer can further comprise a host; wherein the host comprises a triphenylene containing benzo-fused thiophene or benzo-fused furan; wherein any substituent in the host is an unfused substituent independently selected from the group consisting of CnH2n+1, OCnH2n+1, OAr1, N(CnH2n+1)2, N(Ar1)(Ar2), CH═CH—CnH2n+1, C≡CCnH2n+1, Ar1, Ar1-Ar2, CnH2n—Ar1, or no substitution; wherein n is from 1 to 10; and wherein Ar1 and Ar2 are independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
In one embodiment of the device, the organic layer further comprises a host material, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.
In another embodiment of the device, the host material can be a specific compound selected from the group consisting of:













and combinations thereof.

In another embodiment of the device, the host material can include a metal complex.
According to another aspect of the present disclosure, a formulation comprising a compound having a formula Ir(LA)n(LB)3-n, having the structure:




is disclosed.

In Formula I, Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;
wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfanyl, sulfonyl, phosphino, and combinations thereof;
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, deuterium, aryl, alkyl, cycloalkyl, and combinations thereof;
wherein at least two of R1, R2, R3, and R4 are alkyl, cycloalkyl, or combinations thereof; and
wherein any adjacent substitutions in R1 to R4 and Ra to Rc are optionally linked together to form a ring.
In some embodiments, the compound can be an emissive dopant in an OLED. In some embodiments, the compound can produce emissions via phosphorescence, fluorescence, thermally activated delayed fluorescence, i.e., TADF (also referred to as E-type delayed fluorescence), triplet-triplet annihilation, or combinations of these processes.
Combination with Other Materials
The materials described herein as useful for a particular layer in an organic light emitting device may be used in combination with a wide variety of other materials present in the device. For example, emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, blocking layers, injection layers, electrodes and other layers that may be present. The materials described or referred to below are non-limiting examples of materials that may be useful in combination with the compounds disclosed herein, and one of skill in the art can readily consult the literature to identify other materials that may be useful in combination.
HIL/HTL:
A hole injecting/transporting material to be used in the present invention is not particularly limited, and any compound may be used as long as the compound is typically used as a hole injecting/transporting material. Examples of the material include, but are not limited to: a phthalocyanine or porphyrin derivative; an aromatic amine derivative; an indolocarbazole derivative; a polymer containing fluorohydrocarbon; a polymer with conductivity dopants; a conducting polymer, such as PEDOT/PSS; a self-assembly monomer derived from compounds such as phosphonic acid and silane derivatives; a metal oxide derivative, such as MoOx; a p-type semiconducting organic compound, such as 1,4,5,8,9,12-Hexaazatriphenylenehexacarbonitrile; a metal complex, and a cross-linkable compound.
Examples of aromatic amine derivatives used in HIL or HTL include, but are not limited to the following general structures:




Each of Ar1 to Ar9 is selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each Ar is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, Ar1 to Ar9 is independently selected from the group consisting of:




wherein k is an integer from 1 to 20; X101 to X108 is C (including CH) or N; Z101 is NAr1, O, or S; Ar1 has the same group defined above.

Examples of metal complexes used in HIL or HTL include, but are not limited to the following general formula:




wherein Met is a metal, which can have an atomic weight greater than 40; (Y101-Y102) is a bidentate ligand, Y101 and Y102 are independently selected from C, N, O, P, and S; L101 is an ancillary ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k′′ is the maximum number of ligands that may be attached to the metal.

In one aspect, (Y101-Y102) is a 2-phenylpyridine derivative. In another aspect, (Y101-Y102) is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os, and Zn. In a further aspect, the metal complex has a smallest oxidation potential in solution vs. Fc+/Fc couple less than about 0.6 V.
Host:
The light emitting layer of the organic EL device of the present invention preferably contains at least a metal complex as light emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complexes or organic compounds may be used as long as the triplet energy of the host is larger than that of the dopant. While the Table below categorizes host materials as preferred for devices that emit various colors, any host material may be used with any dopant so long as the triplet criteria is satisfied.
Examples of metal complexes used as host are preferred to have the following general formula:




wherein Met is a metal; (Y103-Y104) is a bidentate ligand, Y103 and Y104 are independently selected from C, N, O, P, and S; L101 is an another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k′′ is the maximum number of ligands that may be attached to the metal.

In one aspect, the metal complexes are:




wherein (O—N) is a bidentate ligand, having metal coordinated to atoms O and N.

In another aspect, Met is selected from Ir and Pt. In a further aspect, (Y103-Y104) is a carbene ligand.
Examples of organic compounds used as host are selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each group is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, the host compound contains at least one of the following groups in the molecule:







wherein R101 to R107 is independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. k is an integer from 0 to 20 or 1 to 20; k′′′ is an integer from 0 to 20. X101 to X108 is selected from C (including CH) or N. Z101 and Z102 is selected from NR101, O, or S.

HBL:

A hole blocking layer (HBL) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a blocking layer in a device may result in substantially higher efficiencies as compared to a similar device lacking a blocking layer. Also, a blocking layer may be used to confine emission to a desired region of an OLED.
In one aspect, compound used in HBL contains the same molecule or the same functional groups used as host described above.
In another aspect, compound used in HBL contains at least one of the following groups in the molecule:




wherein k is an integer from 1 to 20; L101 is an another ligand, k′ is an integer from 1 to 3.

ETL:

Electron transport layer (ETL) may include a material capable of transporting electrons. Electron transport layer may be intrinsic (undoped), or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complexes or organic compounds may be used as long as they are typically used to transport electrons.
In one aspect, compound used in ETL contains at least one of the following groups in the molecule:




wherein R101 is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. Ar1 to Ar3 has the similar definition as Ar's mentioned above. k is an integer from 1 to 20. X101 to X108 is selected from C (including CH) or N.

In another aspect, the metal complexes used in ETL include, but are not limited to the following general formula:




wherein (O—N) or (N—N) is a bidentate ligand, having metal coordinated to atoms O, N or N, N; L101 is another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal.

In any above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms can be partially or fully deuterated. Thus, any specifically listed substituent, such as, without limitation, methyl, phenyl, pyridyl, etc. encompasses undeuterated, partially deuterated, and fully deuterated versions thereof. Similarly, classes of substituents such as, without limitation, alkyl, aryl, cycloalkyl, heteroaryl, etc. also encompass undeuterated, partially deuterated, and fully deuterated versions thereof.
In addition to and/or in combination with the materials disclosed herein, many hole injection materials, hole transporting materials, host materials, dopant materials, exciton/hole blocking layer materials, electron transporting and electron injecting materials may be used in an OLED. Non-limiting examples of the materials that may be used in an OLED in combination with materials disclosed herein are listed in Table A below. Table A lists non-limiting classes of materials, non-limiting examples of compounds for each class, and references that disclose the materials.









TABLE A





MATERIAL
EXAMPLES OF MATERIAL
PUBLICATIONS















Hole injection materials









Phthalocyanine and porphyrin compounds




Appl. Phys. Lett. 69, 2160 (1996)


 


Starburst triarylamines




J. Lumin. 72-74, 985 (1997)


 


CFx Fluorohydrocarbon
CHxFyn
Appl. Phys. Lett. 78,


polymer

673 (2001)


 


Conducting polymers (e.g., PEDOT:PSS, polyaniline, polythiophene)




Synth. Met. 87, 171 (1997) WO2007002683


 


Phosphonic acid and silane SAMs




US20030162053


 


Triarylamine or polythiophene polymers with conductivity dopants




EP1725079A1


 










 










 


Organic compounds with conductive inorganic compounds, such as molybdenum and tungsten oxides




US20050123751 SID Symposium Digest, 37, 923 (2006) WO2009018009


 


n-type semiconducting organic complexes




US20020158242


 


Metal organometallic complexes




US20060240279


 


Cross-linkable compounds




US20080220265


 


Polythiophene based polymers and copolymers




WO 2011075644 EP2350216


 







Hole transporting materials









Triarylamines (e.g., TPD, α-NPD)




Appl. Phys. Lett. 51, 913 (1987)


 







U.S. Pat. No. 5,061,569


 







EP650955


 







J. Mater. Chem. 3, 319 (1993)


 







Appl. Phys. Lett. 90, 183503 (2007)


 







Appl. Phys. Lett. 90, 183503 (2007)


 


Triarylamine on spirofluorene core




Synth. Met. 91, 209 (1997)


 


Arylamine carbazole compounds




Adv. Mater. 6, 677 (1994), US20080124572


 


Triarylamine with (di)benzothiophene/ (di)benzofuran




US20070278938, US20080106190 US20110163302


 


Indolocarbazoles




Synth. Met. 111, 421 (2000)


 


Isoindole compounds




Chem. Mater. 15, 3148 (2003)


 


Metal carbene complexes




US20080018221


 







Phosphorescent OLED host materials


Red hosts









Arylcarbazoles




Appl. Phys. Lett. 78, 1622 (2001)


 


Metal 8-hydroxyquinolates (e.g., Alq3, BAlq)




Nature 395, 151 (1998)


 







US20060202194


 







WO2005014551


 







WO2006072002


 


Metal phenoxybenzothiazole compounds




Appl. Phys. Lett. 90, 123509 (2007)


 


Conjugated oligomers and polymers (e.g., polyfluorene)




Org. Electron. 1, 15 (2000)


 


Aromatic fused rings




WO2009066779, WO2009066778, WO2009063833, US20090045731, US20090045730, WO2009008311, US20090008605, US20090009065


 


Zinc complexes




WO2010056066


 


Chrysene based compounds




WO2011086863


 







Green hosts









Arylcarbazoles




Appl. Phys. Lett. 78, 1622 (2001)


 







US20030175553


 







WO2001039234


 


Aryltriphenylene compounds




US20060280965


 







US20060280965


 







WO2009021126


 


Poly-fused heteroaryl compounds




US20090309488 US20090302743 US20100012931


 


Donor acceptor type molecules




WO2008056746


 







WO2010107244


 


Aza-carbazole/DBT/DBF




JP2008074939


 







US20100187984


 


Polymers (e.g., PVK)




Appl. Phys. Lett. 77, 2280 (2000)


 


Spirofluorene compounds




WO2004093207


 


Metal phenoxybenzooxazole compounds




WO2005089025


 







WO2006132173


 







JP200511610


 


Spirofluorene-carbazole compounds




JP2007254297


 







JP2007254297


 


Indolocarbazoles




WO2007063796


 







WO2007063754


 


5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole)




J. Appl. Phys. 90, 5048 (2001)


 







WO2004107822


 


Tetraphenylene complexes




US20050112407


 


Metal phenoxypyridine compounds




WO2005030900


 


Metal coordination complexes (e.g., Zn, Al with N{circumflex over ( )}N ligands)




US20040137268, US20040137267


 







Blue hosts









Arylcarbazoles




Appl. Phys. Lett, 82, 2422 (2003)


 







US20070190359


 


Dibenzothiophene/Di- benzofuran-carbazole compounds




WO2006114966, US20090167162


 







US20090167162


 







WO2009086028


 







US20090030202, US20090017330


 







US20100084966


 


Silicon aryl compounds




US20050238919


 







WO2009003898


 


Silicon/Germanium aryl compounds




EP2034538A


 


Aryl benzoyl ester




WO2006100298


 


Carbazole linked by non- conjugated groups




US20040115476


 


Aza-carbazoles




US20060121308


 


High triplet metal organometallic complex




U.S. Pat. No. 7,154,114


 







Phosphorescent dopants


Red dopants









Heavy metal porphyrins (e.g., PtOEP)




Nature 395, 151 (1998)


 


Iridium(III) organometallic complexes




Appl. Phys. Lett. 78, 1622 (2001)


 







US20030072964


 







US20030072964


 







US20060202194


 







US20060202194


 







US20070087321


 







US20080261076 US20100090591


 







US20070087321


 







Adv. Mater. 19, 739 (2007)


 







WO2009100991


 







WO2008101842


 







U.S. Pat. No. 7,232,618


 


Platinum(II) organometallic complexes




WO2003040257


 







US20070103060


 


Osmium(III) complexes




Chem. Mater. 17, 3532 (2005)


 


Ruthenium(II) complexes




Adv. Mater. 17, 1059 (2005)


 


Rhenium (I), (II), and (III) complexes




US20050244673


 







Green dopants









Iridium(III) organometallic complexes




Inorg. Chem. 40, 1704 (2001)


 







US20020034656


 







U.S. Pat. No. 7,332,232


 







US20090108737


 







WO2010028151


 







EP1841834B


 







US20060127696


 







US20090039776


 







U.S. Pat. No. 6,921,915


 







US20100244004


 







U.S. Pat. No. 6,687,266


 







Chem. Mater. 16, 2480 (2004)


 







US20070190359


 







US 20060008670 JP2007123392


 







WO2010086089, WO2011044988


 







Adv. Mater. 16, 2003 (2004)


 







Angew. Chem. Int. Ed. 2006, 45, 7800


 







WO2009050290


 







US20090165846


 







US20080015355


 







US20010015432


 







US20100295032


 


Monomer for polymeric metal organometallic compounds




U.S. Pat. No. 7,250,226, U.S. Pat. No. 7,396,598


 


Pt(II) organometallic complexes, including polydentate ligands




Appl. Phys. Lett. 86, 153505 (2005)


 







Appl. Phys. Lett. 86, 153505 (2005)


 







Chem. Lett. 34, 592 (2005)


 







WO2002015645


 







US20060263635


 







US20060182992 US20070103060


 


Cu complexes




WO2009000673


 







US20070111026


 


Gold complexes




Chem. Commun. 2906 (2005)


 


Rhenium(III) complexes




Inorg. Chem. 42, 1248 (2003)


 


Osmium(II) complexes




U.S. Pat. No. 7,279,704


 


Deuterated organometallic complexes




US20030138657


 


Organometallic complexes with two or more metal centers




US20030152802


 







U.S. Pat. No. 7,090,928


 







Blue dopants









Iridium(III) organometallic complexes




WO2002002714


 







WO2006009024


 







US20060251923 US20110057559 US20110204333


 







U.S. Pat. No. 7,393,599, WO2006056418, US20050260441, WO2005019373


 







U.S. Pat. No. 7,534,505


 







WO2011051404


 







U.S. Pat. No. 7,445,855


 







US20070190359, US20080297033 US20100148663


 







U.S. Pat. No. 7,338,722


 







US20020134984


 







Angew. Chem. Int. Ed. 47, 4542 (2008)


 







Chem. Mater. 18, 5119 (2006)


 







Inorg. Chem. 46, 4308 (2007)


 







WO2005123873


 







WO2005123873


 







WO2007004380


 







WO2006082742


 


Osmium(II) complexes




U.S. Pat. No. 7,279,704


 







Organometallics 23, 3745 (2004)


 


Gold complexes




Appl. Phys. Lett. 74, 1361 (1999)


 


Platinum(II) complexes




WO2006098120, WO2006103874


 


Pt tetradentate complexes with at least one metal- carbene bond




U.S. Pat. No. 7,655,323


 







Exciton/hole blocking layer materials









Bathocuproine compounds (e.g., BCP, BPhen)




Appl. Phys. Lett. 75, 4 (1999)


 







Appl. Phys. Lett. 79, 449 (2001)


 


Metal 8-hydroxyquinolates (e.g., BAlq)




Appl. Phys. Lett. 81, 162 (2002)


 


5-member ring electron deficient heterocycles such as triazole, oxadiazole, imidazole, benzoimidazole




Appl. Phys. Lett. 81, 162 (2002)


 


Triphenylene compounds




US20050025993


 


Fluorinated aromatic compounds




Appl. Phys. Lett. 79, 156 (2001)


 


Phenothiazine-S-oxide




WO2008132085


 


Silylated five-membered nitrogen, oxygen, sulfur or phosphorus dibenzoheterocycles




WO2010079051


 


Aza-carbazoles




US20060121308


 







Electron transporting materials









Anthracene- benzoimidazole compounds




WO2003060956


 







US20090179554


 


Aza triphenylene derivatives




US20090115316


 


Anthracene-benzothiazole compounds




Appl. Phys. Lett. 89, 063504 (2006)


 


Metal 8-hydroxyquinolates (e.g., Alq3, Zrq4)




Appl. Phys. Lett. 51, 913 (1987) U.S. Pat. No. 7,230,107


 


Metal hydroxybenzoquinolates




Chem. Lett. 5, 905 (1993)


 


Bathocuproine compounds such as BCP, BPhen, etc




Appl. Phys. Lett. 91, 263503 (2007)


 







Appl. Phys. Lett. 79, 449 (2001)


 


5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole, imidazole, benzoimidazole)




Appl. Phys. Lett. 74, 865 (1999)


 







Appl. Phys. Lett. 55, 1489 (1989)


 







Jpn. J. Apply. Phys. 32, L917 (1993)


 


Silole compounds




Org. Electron. 4, 113 (2003)


 


Arylborane compounds




J. Am. Chem. Soc. 120, 9714 (1998)


 


Fluorinated aromatic compounds




J. Am. Chem. Soc. 122, 1832 (2000)


 


Fullerene (e.g., C60)




US20090101870


 


Triazine complexes




US20040036077


 


Zn (N{circumflex over ( )}N) complexes




U.S. Pat. No. 6,528,187









The present disclosure describes novel iridium complexes comprising dialkyl-substituted aza-DBF and 2-phenylpyridine ligands. The dialkyl substitution appears to improve OLED device performance such as CIE color and extending the lifetime.
Molecular modification of iridium complexes can effectively change material device performance. In this disclosure, the inventors discovered that aza-DBF ligand with multi-alkyl-substitution on DBF ring on heteroleptic iridium complex can improve the device lifetime and color CIE. The improved color CIE was unexpected. It was found that in many cases when methyl group is in R1 position the color CIE of the particular compound is always slightly red shifted compared to the non-substituted compounds (e.g. R1 is hydrogen).
DEVICE EXAMPLES
All example devices were fabricated by high vacuum (<10−7 Torr) thermal evaporation. The anode electrode is 1200 Å of indium tin oxide (ITO). The cathode consisted of 10 Å of LiF followed by 1,000 Å of Al. All devices were encapsulated with a glass lid sealed with an epoxy resin in a nitrogen glove box (<1 ppm of H2O and O2) immediately after fabrication, and a moisture getter was incorporated inside the package. The organic stack of the device examples consisted of sequentially, from the ITO surface, 100 Å of LG-101 (available from LG Chem. Inc.) as the hole injection layer (HIL), 450 Å of Compound D as the hole transporting layer (HTL), 400 Å of the invention compound doped in Compound B as host with 10 or 15 weight percent of the iridium phosphorescent compound as the emissive layer (EML), 50 {acute over (Å)} of Compound C as a blocking layer (BL), 450 Å of Alq (tris-8-hydroxyquinoline aluminum) as the ETL. The comparative Example with Compound A was fabricated similarly to the Device Examples. The device results and data are summarized in Tables 1 and 2. As used herein, Alq, Compounds A, B, C and D have the following structures:














TABLE 1







Device Structures of Inventive Compound and Comparative Compound












Device
HIL
HTL
EML (300 Å, doping %)
BL
ETL
















Comparative
LG-101
Compound D
Compound
Compound A
Compound C
Alq


Example 1
100 Å
300 Å
B as host
10%
50 Å
450 Å


Comparative
LG-101
Compound D
Compound
Compound A
Compound C
Alq


Example 2
100 Å
300 Å
B as host
15%
50 Å
450 Å


Inventive
LG-101
Compound D
Compound
Compound 1
Compound C
Alq


Example 1
100 Å
300 Å
B as host
10%
50 Å
450 Å


Inventive
LG-101
Compound D
Compound
Compound 1
Compound C
Alq


Example 2
100 Å
300 Å
B as host
15%
50 Å
450 Å


Inventive
LG-101
Compound D
Compound
Compound 2
Compound C
Alq


Example 3
100 Å
300 Å
B as host
10%
50 Å
450 Å


Inventive
LG-101
Compound D
Compound
Compound 2
Compound C
Alq


Example 4
100 Å
300 Å
B as host
15%
50 Å
450 Å
















TABLE 2







VTE Device Results















λmax
FWHM
Dopant


Device
x
y
(nm)
(nm)
(%)















Comparative Example 1
0.337
0.630
528
59
10


(Dopant Compound A)


Comparative Example 2
0.344
0.627
530
60
15


(Dopant Compound A)


Inventive Example 1
0.310
0.640
520
61
10


(Dopant Compound 1)


Inventive Example 2
0.315
0.638
520
63
15


(Dopant Compound 1)


Inventive Example 3
0.332
0.632
526
60
10


(Dopant Compound 2)


Inventive Example 4
0.339
0.628
528
61
15


(Dopant Compound 2)









Table 2 is the summary of EL of comparative and inventive devices at 1000 nits. The emission wavelengths of invention Compound 1 and Compound 2 emission peak max with doping concentration at 10% were 520 nm and 526 nm. Compared to the comparative Compound A, which exhibited emission peak max of 528 nm at 10% doping concentration, the inventive compounds blue shifted about 8 and 2 nm, respectively. Similarly, the emission wavelengths of invention Compound 1 and Compound 2 at doping concentration of 15% were 520 nm and 528 nm, respectively, whereas the comparative Compound A exhibited emission peak max of 530 nm. Thus, the emission wavelengths of the inventive compounds blue shifted at 15% doping concentration also. The device results demonstrate that multi-alkylation can result in blue shift of emission spectrum which is a desired property for OLED device.
Synthesis Example 1 for an Example of the Novel Compound, Compound IrLA8(LB1)2




An iridium precursor (1.69 g, 2.368 mmol) and 2,4-bis(methyl-d3)-8-(pyridin-2-yl)benzofuro[2,3-b]pyridine (0.996 g, 3.55 mmol) were added to a 100 mL round-bottom flask equipped with a magnetic stir bar. Anhydrous DMF (25 mL) and 2-ethoxyethanol (25 mL) were added to the reaction mixture. The reaction flask was then placed into an oil bath and gradually heated to 130° C. for 16 hours. Then, the reaction mixture was concentrated in a vacuum. The residue was then dissolved in CH2Cl2, filtered through a pad of Celite, eluting with CH2Cl2 and EtOAc, and concentrated in a vacuum. The crude product was purified via flash chromatography on a (2×120) g column (CH2Cl2) to provide Compound IrLA8(LB1)2 as an orange powder (0.77 g, 41%).
Synthesis Example 2 for an Example of the Novel Compound, Compound IrLA7(LB1)2




An iridium precursor (1.85 g, 2.59 mmol) and 2,3-bis(methyl-d3)-8-(pyridin-2-yl)benzofuro[2,3-b]pyridine (1.09 g, 3.89 mmol) were added to a 100 mL round-bottom flask equipped with a magnetic stir bar. Anhydrous DMF (26 mL) and 2-ethoxyethanol (26 mL) were added to the reaction mixture. The reaction flask was then placed into an oil bath, gradually heated to 130° C. for 16 hours. Then, the reaction mixture was concentrated in a vacuum. The residue was then dissolved in CH2Cl2, filtered through a pad of celite, eluting with CH2Cl2 and EtOAc, and concentrated in a vacuum. The crude product was purified via flash chromatography on a (2×220) g column (CH2Cl2) to provide Compound IrLA7(LB1)2 as an orange solid (1.0 g, 49%).
Synthesis Example 3 for an Example of the Novel Compound, Compound IrLA9(LB1)2




A mixture of iridium precursor (2.1 g, 2.94 mmol), aza dibenzofuran pyridine ligand (1.485 g, 5.3 mmol), 2-ethoxyethanol (30 mL) and DMF (30 mL) was heated at 130° C. for 18 hours. The reaction mixture was concentrated to remove solvents and filtered through a small plug of silica gel and further chromatographed to give 1.2 g of Compound IrLA9(LB1)2 (52.3% yield).
Synthesis Example 4 for an Example of the Novel Compound, Compound IrLA9(LB12)2




A mixture of iridium precursor (2.3 g, 2.94 mmol), aza dibenzofuran pyridine ligand (1.485 g, 5.29 mmol), 2-ethoxyethanol (30 mL) and DMF (30 mL) was heated at 130° C. for 18 hours. The reaction mixture was concentrated to remove solvents and filtered through a small plug of silica gel and further chromatographed to give 0.47 g of Compound IrLA9(LB12)2 (18.8% yield).
Synthesis Example 5 for an Example of the Novel Compound, Compound IrLA81(LB1)2




A mixture of iridium precursor (1.35 g, 1.89 mmol), aza dibenzofuran pyridine ligand (0.935 g, 2.84 mmol), 2-ethoxyethanol (30 mL) and DMF (30 mL) was heated at 130° C. for 18 hours. The reaction mixture was concentrated to remove solvents and filtered through a small plug of silica gel and further chromatographed to give 0.77 g of Compound IrLA81(LB1)2 (49.1% yield).
Synthesis Example 6 for an Example of the Novel Compound, Compound IrLA81(LB9)2




A mixture of iridium precursor (2.1 g, 2.001 mmol), aza dibenzofuran pyridine ligand (0.991 g, 3.01 mmol), 2-ethoxyethanol (30 mL) and DMF (30 mL) was heated at 130° C. for 18 hours. The reaction mixture was concentrated to remove solvents and filtered through a small plug of silica gel and further chromatographed to give 0.86 g of Compound IrLA81(LB9)2 (49.7% yield).
Synthesis Example 7 for an Example of the Novel Compound, Compound IrLA80(LB9)2




A mixture of iridium precursor (0.93 g, 1.23 mmol), aza dibenzofuran pyridine ligand (0.608 g, 1.845 mmol), 2-ethoxyethanol (13 mL) and DMF (13 mL) was heated at 130° C. for 19 hours. The reaction mixture was concentrated to remove solvents and filtered through a small plug of silica gel and further chromatographed to give 0.43 g of Compound IrLA80(LB9)2 (40.5% yield).
It is understood that the various embodiments described herein are by way of example only, and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without deviating from the spirit of the invention. The present invention as claimed may therefore include variations from the particular examples and preferred embodiments described herein, as will be apparent to one of skill in the art. It is understood that various theories as to why the invention works are not intended to be limiting.

## Claims

1. A compound having the formula Ir(LA)n(LB)3-n, having the structure:



wherein Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;
wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein (i) R1 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R3 are hydrogen, or (ii) R1, R3, and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated and R2 is hydrogen; and
wherein any two substituents among Ra to Rc or R3 and R4 in option (ii) are optionally linked together to form a ring.

2. The compound of claim 1, wherein, when R1, R3, and R4 are alkyl or cycloalkyl, each is independently selected from the group consisting of methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, and combinations thereof, wherein each group is optionally partially or fully deuterated.

3. The compound of claim 1, wherein n is 1.

4. The compound of claim 1, wherein X is O.

5. The compound of claim 1, wherein R1 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R3 are hydrogen.

6. The compound of claim 1, wherein R1, R3, and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated and R2 is hydrogen.

7. The compound of claim 1, wherein the total carbon number of R1, R2, R3, and R4 are at least 3.

8. The compound of claim 1, wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.

9. The compound of claim 1, wherein LA has a structure according to the following formula:



and is selected from the group consisting of LA1, LA1, LA9, LA15, LA21, LA27, LA33, LA39, LA45, LA51, LA57, LA63, LA69, LA75, LA81, LA87, LA93, LA100, LA106, LA109, LA110, LA113, LA122, LA123, LA124, LA133, LA139, LA145, LA151, LA157, LA163, LA169, LA175, LA181, LA187, LA1193, LA205, LA211, LA217, LA223, LA229, LA237, LA238, LA242, LA245, LA248, LA250, LA255, LA256, LA260, LA263, LA266, LA273, LA274, LA278, LA281, LA284, LA286, LA291, LA292, LA296, LA299, LA304, LA305, LA308, LA312, LA314, LA315, LA317, LA321-LA339, LA343-LA351, LA359, LA363, LA368, LA372, LA377, LA381, LA386, LA390, LA393, LA396, LA402, LA408, LA415, LA421, LA427, LA431 and LA434-LA438, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in Tables 1A and 1B shown below:
















TABLE 1A





Ligand










LA
R1
R2
R3
R4
R5
R6
R7
R8







LA3
CH3
H
H
CH3
H
H
H
H


LA9
CD3
H
H
CD3
H
H
H
H


LA15
CH3
H
H
CH3
CH3
H
H
H


LA21
CD3
H
H
CD3
CD3
H
H
H


LA27
CH3
H
H
CH3
H
CH3
H
H


LA33
CD3
H
H
CD3
H
CD3
H
H


LA39
CH3
H
H
CH3
H
H
CH3
H


LA45
CD3
H
H
CD3
H
H
CD3
H


LA51
CH3
H
H
CH3
H
H
H
CH3


LA57
CD3
H
H
CD3
H
H
H
CD3


LA63
CH3
H
H
CH3
CH(CH3)2
H
H
H


LA69
CD3
H
H
CD3
CD(CD3)2
H
H
H


LA75
CH3
H
H
CH3
H
CH(CH3)2
H
H


LA81
CD3
H
H
CD3
H
CD(CD3)2
H
H


LA87
CH3
H
H
CH3
H
H
CH(CH3)2
H


LA93
CD3
H
H
CD3
H
H
CD(CD3)2
H


LA100
CH2CH3
H
H
CH3
H
CH(CH3)2
H
H


LA106
CH3
H
H
CH2CH3
H
CH(CH3)2
H
H


LA109
CD2CD3
H
H
CD3
H
CD(CD3)2
H
H


LA110
CD2CD3
H
H
CD3
H
CD(CH3)2
H
H


LA113
CH2CH3
H
H
CH3
H
H
CH(CH3)2
H


LA119
CH3
H
H
CH2CH3
H
H
CH(CH3)2
H


LA122
CD2CD3
H
H
CD3
H
H
CD(CD3)2
H


LA123
CD3
H
H
CD2CH3
H
H
CD(CH3)2
H


LA124
CD3
H
H
CD2CH3
H
H
H
CD3


LA127
CH3
H
H
CH3
H
H
H
CH(CH3)2


LA133
CD3
H
H
CD3
H
H
H
CD(CD3)2


LA139
CH3
H
H
CH3
H
CH2CH(CH3)2
H
H


LA145
CD3
H
H
CD3
H
CD2CH(CH3)2
H
H


LA151
CH3
H
H
CH3
H
H
CH2CH(CH3)2
H


LA157
CD3
H
H
CD3
H
H
CD2CH(CH3)2
H


LA163
CH3
H
H
CH3
CH3
CH3
H
H


LA169
CD3
H
H
CD3
CD3
CD3
H
H


LA175
CH3
H
H
CH3
H
CH3
CH3
H


LA181
CD3
H
H
CD3
H
CD3
CD3
H


LA187
CH3
H
H
CH3
H
CH(CH3)2
CH3
H


LA193
CD3
H
H
CD3
H
CD(CD3)2
CD3
H


LA199
CH3
H
H
CH3
H
CH3
CH(CH3)2
H


LA205
CD3
H
H
CD3
H
CD3
CD(CD3)2
H


LA211
CH3
H
H
CH3
H
CH2CH(CH3)2
CH3
H


LA217
CD3
H
H
CD3
H
CD2CH(CH3)2
CD3
H


LA223
CH3
H
H
CH3
H
CH3
CH2CH(CH3)2
H


LA229
CD3
H
H
CD3
H
CD3
CD2CH(CH3)2
H


LA237
CH(CH3)2
H
H
CH3
H
H
H
H


LA238
CH3
H
H
CH(CH3)2
H
H
H
H


LA242
CH(CH3)2
H
H
CH(CH3)2
H
H
H
H


LA245
CD(CH3)2
H
H
CD3
H
H
H
H


LA248
CD3
H
H
CD(CH3)2
H
H
H
H


LA250
CD(CH3)2
H
H
CD(CH3)2
H
H
H
H


LA255
CH(CH3)2
H
H
CH3
H
CH(CH3)2
H
H


LA256
CH3
H
H
CH(CH3)2
H
CH(CH3)2
H
H


LA260
CH(CH3)2
H
H
CH(CH3)2
H
CH(CH3)2
H
H


LA263
CD(CH3)2
H
H
CD3
H
CD(CD3)2
H
H


LA266
CD3
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA268
CD(CH3)2
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA273
CH(CH3)2
H
H
CH3
H
CH3
CH(CH3)2
H


LA274
CH3
H
H
CH(CH3)2
H
CH3
CH(CH3)2
H


LA278
CH(CH3)2
H
H
CH(CH3)2
H
CH3
CH(CH3)2
H


LA281
CD(CH3)2
H
H
CD3
H
CD3
CH(CH3)2
H


LA284
CD3
H
H
CD(CH3)2
H
CD3
CH(CH3)2
H


LA286
CD(CH3)2
H
H
CD(CH3)2
H
CD3
CH(CH3)2
H


LA291
CH(CH3)2
H
H
CH3
H
CH(CH3)2
CH3
H


LA292
CH3
H
H
CH(CH3)2
H
CH(CH3)2
CH3
H


LA296
CH(CH3)2
H
H
CH(CH3)2
H
CD(CH3)2
CH3
H


LA299
CD(CH3)2
H
H
CD3
H
CD(CH3)2
CD3
H


LA302
CD3
H
H
CD(CH3)2
H
CD(CH3)2
CD3
H


LA304
CD(CH3)2
H
H
CD(CH3)2
H
CD(CH3)2
CD3
H


LA305
CD(CH3)2
H
H
CD(CH3)2
H
CD(CD3)2
CD3
H


LA308
CD3
H
H
CD3
H
CD(CH3)2
H
H


LA312
CH3
CH3
CH3
CH3
H
H
H
H


LA314
CH3
H
CH3
CH3
H
H
H
H


LA315
H
CH3
CH3
CH3
H
H
H
H


LA317
CD3
H
CD3
CD3
H
H
H
H


LA321
CD3
H
CD3
CD3
H
CD(CD3)2
H
H


LA322
CD3
H
CD3
CD3
H
H
CD(CD3)2
H


LA323
CD3
H
CD3
CD3
H
CD(CD3)2
CD3
H


LA324
CD3
H
CD3
CD3
H
CD3
CD(CD3)2
H


LA325
CD3
H
CD3
CD(CH3)2
H
H
H
H


LA326
CD3
H
CD3
CD(CH3)2
H
CD(CD3)2
H
H


LA327
CD3
H
CD3
CD(CH3)2
H
H
CD(CD3)2
H


LA328
CD3
H
CD3
CD(CH3)2
H
CD(CD3)2
CD3
H


LA329
CD3
H
CD3
CD(CH3)2
H
CD3
CD(CD3)2
H


LA330
CD3
H
CD(CH3)2
CD3
H
H
H
H


LA331
CD3
H
CD(CH3)2
CD3
H
CD(CD3)2
H
H


LA332
CD3
H
CD(CH3)2
CD3
H
H
CD(CD3)2
H


LA333
CD3
H
CD(CH3)2
CD3
H
CD(CD3)2
CD3
H


LA334
CD3
H
CD(CH3)2
CD3
H
CD3
CD(CD3)2
H


LA335
CD3
H
CD(CH3)2
CD(CH3)2
H
H
H
H


LA336
CD3
H
CD(CH3)2
CD(CH3)2
H
CD(CD3)2
H
H


LA337
CD3
H
CD(CH3)2
CD(CH3)2
H
H
CD(CD3)2
H


LA338
CD3
H
CD(CH3)2
CD(CH3)2
H
CD(CD3)2
CD3
H


LA339
CD3
H
CD(CH3)2
CD(CH3)2
H
CD3
CD(CD3)2
H


LA343
CD(CH3)2
H
CD3
CD3
H
H
H
H


LA344
CD(CH3)2
H
CD3
CD3
H
CD(CD3)2
H
H


LA345
CD(CH3)2
H
CD3
CD3
H
H
CD(CD3)2
H


LA346
CD(CH3)2
H
CD3
CD3
H
CD3
CD(CD3)2
H


LA347
CD(CH3)2
H
CD3
CD3
H
CD(CD3)2
CD3
H


LA348
CD3
H
H
CD(CH3)2
H
CD(CD3)2
H
H


LA349
CD3
H
H
CD(CH3)2
H
H
CD(CD3)2
H


LA350
CD3
H
H
CD(CH3)2
H
CD(CD3)2
CD3
H


LA351
CD3
H
H
CD(CH3)2
H
CD3
CD(CD3)2
H
























TABLE 1B





Ligand










LA
R1
R2
R3
R4
R5
R6
R7
R8







LA359




H
H
CH3
H
H
H
H


 


LA363
CH3
H
H




H
H
H
H


 


LA368




H
H
CD3
H
H
H
H


 


LA372
CD3
H
H




H
H
H
H


 


LA377




H
H
CH3
H
H
H
H


 


LA381
CH3
H
H




H
H
H
H


 


LA386




H
H
CD3
H
H
H
H


 


LA390
CD3
H
H




H
H
H
H


 


LA393




H
H
CH3
H
H
CH3
H


 


LA396




H
H
CH3
H
CH(CH3)2
H
H


 


LA402




H
H
CD3
H
CD(CD3)2
H
H


 


LA408




H
H
CD3
H
CD(CH3)2
H
H


 


LA415




H
H
CH3
H
CH(CH3)2
H
H


 


LA421




H
H
CD3
H
CD(CD3)2
H
H


 


LA427




H
H
CD3
H
CD(CH3)2
H
H


 


LA431
CD3
H
H




H
CD(CH3)2
H
H


 


LA434




H
H




H
CD(CH3)2
H
H


 


LA435




H
H




H
CD(CH3)2
H
H


 


LA436




H
H




H
CD(CH3)2
H
H


 


LA437




H
H




H
CD(CH3)2
H
H


 


LA438




H
H




H
CD(CH3)2
H
H.

10. The compound of claim 1, wherein LB is selected from the group consisting of:

11. The compound of claim 1, wherein the compound is selected from the group consisting of:

12. A device comprising one or more organic light emitting devices, at least one of the one or more organic light emitting devices comprising:
an anode;
a cathode; and
an organic layer, disposed between the anode and the cathode, the organic layer comprising a compound having a formula Ir(LA)n(LB)3-n, having the structure:




wherein Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;
wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein (i) R1 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R3 are hydrogen, or (ii) R1, R3, and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated and R2 is hydrogen; and
wherein any two substituents among R1 to R4 and Ra to Rc are optionally linked together to form a ring.

13. The device of claim 12, wherein the device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel.

14. The device of claim 12, wherein the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant.

15. The device of claim 12, wherein the organic layer further comprises a host; wherein the host comprises a triphenylene containing benzo-fused thiophene or benzo-fused furan;
wherein any substituent in the host is an unfused substituent independently selected from the group consisting of CnH2n+1, OCnH2n+1, OAr1, N(CnH2n+1)2, N(Ar1)(Ar2), CH═CH—CnH2n+1, C≡CCnH2n+1, Ar1, Ar1-Ar2, CnH2n—Ar1, or no substitution;
wherein n is from 1 to 10; and
wherein Ar1 and Ar2 are independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.

16. The device of claim 12, wherein the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.

17. The device of claim 12, wherein the organic layer further comprises a host and the host is selected from the group consisting of:












and combinations thereof.

18. A formulation comprising a compound having a formula Ir(LA)n(LB)3-n, having the structure:



wherein Ra, Rb, and Rc each independently represent mono-, di-, tri-, tetra-substitution, or no substitution;
wherein X is O, S, or Se;
wherein n is an integer from 1 to 3;
wherein Ra, Rb, and Rc are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfanyl, sulfonyl, phosphino, and combinations thereof;
wherein (i) R1 and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated, and R2 and R3 are hydrogen, or (ii) R1, R3, and R4 are each independently selected from the group consisting of alkyl, cycloalkyl, and combinations thereof, wherein each group is optionally partially or fully deuterated and R2 is hydrogen; and
wherein any two substituents among R1 to R4 and Ra to Rc are optionally linked together to form a ring.